Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.05 +0.35 (+1.26%)
Official Closing Price Updated: 7:00 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,268,703
Open 27.76
Bid (Size) 28.00 (13)
Ask (Size) 28.02 (12)
Prev. Close 27.70
Today's Range 27.67 - 28.09
52wk Range 25.20 - 37.80
Shares Outstanding 5,606,688,356
Dividend Yield 5.85%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With $100 in July
Adding these dividend payers to your portfolio is a nearly certain way to boost your passive income stream. 
Via The Motley Fool
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis... 
Via Benzinga

Performance

YTD
-5.65%
-5.65%
1 Month
-2.60%
-2.60%
3 Month
+5.53%
+5.53%
6 Month
-5.17%
-5.17%
1 Year
-21.05%
-21.05%

More News

Read More
3 Stock Giants Analysts Are Bullish On Despite Struggles
Via MarketBeat
3 Dividend Stocks That Are Screaming Buys in July
Via The Motley Fool
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
What the Options Market Tells Us About Pfizer
Via Benzinga
A Glimpse Into The Expert Outlook On Pfizer Through 9 Analysts
Via Benzinga
7 Juicy Dividend Stocks That Have Grown for More Than a Decade
Via InvestorPlace
How To Buy Growth Stocks In An Economy That Isn’t Growing
Via Talk Markets
Topics Economy Stocks
Exposures Economy US Equities
AbbVie Stock: A Perfect Dip for Investors to Buy
Via MarketBeat
Topics ETFs
3 Undervalued Stocks Poised for a Jaw-Dropping Breakout
Via InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Via Benzinga
Exposures COVID-19
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Via MarketBeat
Exposures Product Safety
London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Via MarketBeat
Topics ETFs
Exposures COVID-19
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock
Via The Motley Fool
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Via InvestorPlace
Time to Pounce: 2 Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought for the Second Half of 2024 (and Beyond)
Via The Motley Fool
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Amazon Web Services Focuses On The Future, Anticipating AI Challenges Years In Advance To Deliver 'True Value' For Customers
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
Via InvestorPlace
2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
Via The Motley Fool
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.